deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 1-arm NCT03459170

Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant

A Phase I Study Of Safety, Pharmacokinetics, And Efficacy Of Donor BPX-501 Cells and Rimiducid Infusion For Children With Recurrent Hematologic Malignancies or Minimal Residual Disease After Allogeneic Transplant

Sponsor: Bellicum Pharmaceuticals

Conditions Hematologic Malignancy
Interventions BPX-501 T cells rimiducid
Updated 11 times since 2018 Last updated: Jul 10, 2022 Started: Feb 1, 2018 Primary completion: Sep 30, 2022 Completion: Sep 30, 2035
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03459170, this PHASE1 trial focuses on Hematologic Malignancy and remains ongoing. Sponsored by Bellicum Pharmaceuticals, it has been updated 11 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshotRecruiting~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshotRecruiting~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshotRecruiting~Oct 2018 – ~Oct 2019 · 12 months · monthly snapshotRecruiting~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshotRecruiting~Nov 2019 – ~Nov 2020 · 12 months · monthly snapshotRecruiting~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshotActive Not Recruiting~Jan 2021 – ~Sep 2022 · 20 months · monthly snapshotActive Not Recruiting~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshotActive Not Recruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotActive Not Recruiting~Sep 2024 – present · 22 months · monthly snapshotActive Not Recruiting

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Active Not Recruiting PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  3. Sep 2022 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

  4. Jan 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1

  5. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

▶ Show 6 earlier versions

  1. Nov 2019 — Nov 2020 [monthly]

    Recruiting PHASE1

  2. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE1

  3. Oct 2018 — Oct 2019 [monthly]

    Recruiting PHASE1

  4. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE1

  5. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE1

  6. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

    First recorded

Feb 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bellicum Pharmaceuticals
Data source: Bellicum Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations